CALGARY, AB — January 5, 2026 — Leads & Copy — Seegnal Inc. (TSXV: SEGN) has enhanced its artificial intelligence capabilities with the appointment of Yura Zharkovsky as Vice President of Artificial Intelligence (VP AI) at Seegnal eHealth Ltd., the Company’s operating subsidiary in Israel.
Effective January 4, 2026, the appointment represents a strategic move in Seegnal’s mission to build the Intelligence Layer of Prescriptions and accelerate the development of Seegnal Guard, the company’s next-generation, AI-enhanced, human-led prescription intelligence system.
As Seegnal advances toward becoming a global Prescription Intelligence Platform, Zharkovsky will lead the technical evolution of the Company’s AI stack. He will expand Seegnal Guard’s predictive and personalization capabilities while preserving Seegnal’s core principle: AI that augments clinical judgment.
Zharkovsky previously served as Head of AI at NeuroKaire, where he led the development of an AI-supported clinical system designed to assist in selecting appropriate treatments for patients with major depressive disorder. He also held senior data science and machine learning leadership roles, focusing on translating complex clinical and biomedical data into deployable, high-reliability AI systems used in real-world care environments.
According to the release, Zharkovsky shares Seegnal’s values of transparency, clinical accountability, and measurable impact. His work emphasizes explainability, clinician trust, and real-world adoption, which are foundational to Seegnal Guard’s design and market differentiation.
Seegnal CEO Elad Bibi-Aviv said he has seen firsthand Zharkovsky’s ability to build healthcare technology at the intersection of clinical practice and data execution. He added that Zharkovsky is the ideal leader to help turn prescribing into a measurable, AI-led, governable capability across the enterprise.
Zharkovsky said joining Seegnal is a natural progression of his work with Bibi-Aviv. He added that Seegnal is a platform built on real-world prescribing data and the actual behaviors of clinicians in workflow. Zharkovsky said he looks forward to scaling Seegnal Guard and the broader Intelligence Layer to ensure that every prescription decision is safer, more consistent and more aligned with both patient outcomes and system-wide value.
Seegnal aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal’s Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal’s SaaS technology integrates patient-specific data such as genetics, lab results, ECG, smoking status, allergies, food interactions, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%.
Clinicians using Seegnal eHealth complete their prescription workflow with limited interruption. Patients enjoy more tailored medication and improved safety, leading to better quality of life, with precision alerts reaching up to 98% accuracy. Institutions have reported reductions in admissions, medication consumption, and significant time savings in prescription renewals.
Seegnal eHealth is marketing its SaaS-based platform in Israel, the United Arab Emirates, the United Kingdom, the United States, and Poland. The platform is currently a “standard of care” system for over 10,000 clinicians in Israel.
Contact:
Elad Bibi-Aviv, CEO of Seegnal.
Source: Seegnal Inc.
